Kyverna Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Kyverna Therapeutics has a total shareholder equity of $361.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $390.0M and $29.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$369.79m |
| Equity | US$360.99m |
| Total liabilities | US$28.99m |
| Total assets | US$389.98m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: KYTX's short term assets ($375.5M) exceed its short term liabilities ($21.9M).
Long Term Liabilities: KYTX's short term assets ($375.5M) exceed its long term liabilities ($7.1M).
Debt to Equity History and Analysis
Debt Level: KYTX is debt free.
Reducing Debt: KYTX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KYTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: KYTX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 38.2% each year.